Inavir TwinCaps launches in Japan

Published: 22-Oct-2010
Drug Delivery Finance Pharmaceutical

Daiichi Sankyo will supply four million packs by March 2011


Daiichi Sankyo Company has launched Inavir, an inhalation powder delivered by Hovione’s TwinCaps inhaler to treat influenza in Japan.

Hovione of Portugal designed TwinCaps specifically for this indication. It is licensed to Daiichi Sankyo of Japan and to Australia-based Biota Holdings.

Daiichi Sankyo has demonstrated that one 40mg dose of the Inavir active ingredient, laninamivir octanoate, is as effective as oseltamivir, a drug that requires a five-day course of treatment.

The company plans to supply the Japanese market with four million packs by end of March 2011. Half will be supplied by end of 2010.

The reimbursement price of the pack for adult treatment has been set at JPY4,161 (€36; US$50).

  • Companies:
  • Hovione
See more

You may also like

Drug Delivery

Hovione expands nasal drug delivery capabilities

Read more
In collaboration with IDC, the nasal powder delivery device technology provides a good alternative to conventional delivery routes for both local and systemic drug delivery

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  3. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
  4. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  5. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Drug Delivery

Hovione expands nasal drug delivery capabilities

In collaboration with IDC, the nasal powder delivery device technology provides a good alternative to conventional delivery routes for both local and systemic drug delivery
Ingredients

Hovione acquires ExtremoChem and its portfolio of proprietary sugars

The acquisition provides Hovione with new high-performance functional materials, which have shown potential in stabilising biopharmaceuticals
Distribution

Hovione and Presspart extend technology partnership

The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased
Manufacturing

Hovione enters partnership with Ripple Therapeutics

The move is set to expand the use of Ripple's Epidel platform beyond ophthalmic applications
Manufacturing

Hovione and Ji Xing announce licence agreement

Under the license agreement, Ji Xing Pharmaceuticals will receive global rights to JX08 and lead the life cycle of development from preclinical through commercialisation
Manufacturing

Hovione and Zerion Pharma announce technology partnership 

The companies’ expertise and technology will be combined to address the problem of low drug solubility
Manufacturing

Hovione invests $170m in global capacity and capabilities

The company will be investing in its units in Portugal, Ireland and New Jersey
Subscribe now